Sharon Brownlow and Patrick Lansky have been appointed business development managers at Cobra Biologics. Both will be responsible for driving growth in Europe and North America. Previously, Ms. Brownlow served as a sales and marketing manager for Applikon Biotechnology, a bioreactor manufacturer. She has 15 years of experience in up and downstream processing sales and a strong scientific background in protein biochemistry.
Mr. Lansky has worked in the biotech industry for the past 16 years. He has spent the last 11 years working in sales, including four years in the CMO business. He began his career working with Idec Pharmaceuticals.
Also, Elisabeth Lindner, Carl Johan Sundberg and Jinyue Wang, have been appointed non-executive directors to Cobra Biologics’ board. Elisabeth Lindner also serves as chairman and chief executive officer of Biosource Europe AB and a board member of BioInvent International AB, KaroBio AB and Pharmalink AB. She has significant senior management experience with Pharmacia Corp., Octapharma AB and Diamyd Medical AB.